

Lipidor presents Nomination Committee

STOCKHOLM, Sweden, 5th December 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today presents its Nomination Committee, which shall have four members, in accordance with the applicable instructions resolved by the Annual General Meeting 2020.

The three largest shareholders who are registered with Euroclear Sweden AB on the last of September before the meeting are to be contacted by the company's Chairman of the Board. These three largest shareholders have the right to appoint a member of the Nomination Committee. In addition, the Chairman of the Board shall be a member of the Nomination Committee.

As of 30th September 2023, the three largest shareholders were Cerbios-Pharma SA, Aurena Laboratories AB, and Jan Holmbäck. All have agreed to be part of the Nomination Committee.

The Nomination Committee consists of the following members:

- Anton van Troostenburg, appointed by Cerbios-Pharma SA
- Magnus Hedman, appointed by Aurena Laboratories AB
- Jan Holmbäck, appointed by Jan Holmbäck
- Fredrik Sjövall, Chairman of the Board, convener

No later than six weeks before the Annual General Meeting, the Nomination Committee shall submit proposals regarding: Chairman of the AGM; Chairman, other Board members and any Deputy Board members; fees to the Chairman and other Board members; election of auditor and fees to the auditor; and, where applicable, changes in these instructions and rules of procedure for the nomination committee.

The nomination committee's proposals will be presented in the notice convening the Annual General Meeting 2024 and on the company's website, www.lipidor.se. Shareholders who wish to submit proposals to Lipidor's nomination committee for the 2024 Annual General Meeting may do so by e-mail to: info@lipidor.se (title e-mail with the "Nomination Committee") or by letter to the address: Lipidor AB, FAO: Nomination Committee, C/o Ekonomistubben, Box 55931, 102 16 Stockholm.

Lipidor's Annual General Meeting 2024 will be held on Wednesday 5th June 2024 at 10.00am in Danderyd. A request to have a matter dealt with at the meeting must be received no later than 17th April 2024 in order to be included in the notice.

Publication

The information was provided for publication by Lipidor's CEO on 5th December 2023 at 3.00 pm (CET).

For more information, please contact:

Ola Holmlund, CEO

Telephone: +46 (0) 72 50 70 369

Email: ola.holmlund@lipidor.se

The company's Certified Adviser is Carnegie Investment Bank AB (publ).

About Lipidor AB

Lipidor AB (Nasdaq First North Growth Market: LIPI) (www.lipidor.se) is a pharmaceutical development company with a pipeline of pharmaceutical development projects in preclinical and clinical phases. The company can develop topical medical products for the treatment of diseases such as psoriasis, acne vulgaris, bacterial skin infections and atopic dermatitis by reformulation of proven pharmaceutical substances. Lipidor's priority project is AKP02G2, which focusses on psoriasis.

Attachments

[Lipidor presents Nomination Committee](#)